MED12 and non-small cell lung carcinoma: Huang et al. [12] demonstrated that cytosolic MED12 led to the inhibition of epithelial-mesenchymal transition (EMT) through physiological contact with TGF-βRII, which conferred susceptibility of NSCLC cell lines to cytotoxic chemotherapy such as cisplatin.